Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral Drawbacks

Overview

Journal Behav Neurol

Publisher Wiley

Specialty Psychiatry

Date 2015 Sep 9

PMID 26346755

Citations 21

Authors

L Ganau

M Paris

G K Ligarotti

M Ganau

Affiliations

Soon will be listed here.

Abstract

The advancements in basic sciences and the availability of sophisticated technological aids to surgical removal of gliomas have led over the last few years to the rise of innovative surgical strategies, the identification of better prognostic/predictive biomolecular factors, and the development of novel drugs and all are meant to profoundly impact the outcome of patients diagnosed with these aggressive tumours. Unfortunately, the treatment protocols available nowadays still confer only a small survival advantage at a potentially high cost in terms of overall well-being. In this review we identified the potential and limits of the most promising research trends in the management of glioma patients, also highlighting the related externalities. Finally, we focused our attention on the imbalance between the technical and behavioral aspects pertinent to this research area, which ultimately represent the two sides of the same coin.

Citing Articles

Towards a New Dawn for Neuro-Oncology: Nanomedicine at the Service of Drug Delivery for Primary and Secondary Brain Tumours.

Khilar S, Dembinska-Kenner A, Hall H, Syrmos N, Ligarotti G, Plaha P Brain Sci. 2025; 15(2).

PMID: 40002469 PMC: 11852924. DOI: 10.3390/brainsci15020136.

T2-FLAIR imaging-based radiomic features for predicting early postoperative recurrence of grade II gliomas.

Wang Z, Shu J, Feng L Future Oncol. 2024; 20(35):2757-2764.

PMID: 39268928 PMC: 11572138. DOI: 10.1080/14796694.2024.2397327.

Neurosteroids in Glioma: A Novel Therapeutic Concept.

Hogan A, Mut M Life (Basel). 2024; 14(8).

PMID: 39202716 PMC: 11355226. DOI: 10.3390/life14080975.

Whole genome sequencing in (recurrent) glioblastoma: challenges related to informed consent procedures and data sharing.

Hasner M, van Opijnen M, de Vos F, Cuppen E, Broekman M Acta Neurochir (Wien). 2024; 166(1):266.

PMID: 38874628 PMC: 11178618. DOI: 10.1007/s00701-024-06158-z.

Correlations between intravoxel incoherent motion-derived fast diffusion and perfusion fraction parameters and VEGF- and MIB-1-positive rates in brain gliomas: an intraoperative MR-navigated, biopsy-based histopathologic study.

Sheng Y, Dang X, Zhang H, Rui W, Wang J, Cheng H Eur Radiol. 2023; 33(8):5236-5246.

PMID: 36941492 DOI: 10.1007/s00330-023-09506-2.

References

Herbet G, Lafargue G, Moritz-Gasser S, de Champfleur N, Costi E, Bonnetblanc F . A disconnection account of subjective empathy impairments in diffuse low-grade glioma patients. Neuropsychologia. 2015; 70:165-76. DOI: 10.1016/j.neuropsychologia.2015.02.015. View

Raizer J, Fitzner K, Jacobs D, Bennett C, Liebling D, Luu T . Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2014; 11(1):e59-65. PMC: 4295423. DOI: 10.1200/JOP.2012.000560. View

Sagberg L, Jakola A, Solheim O . Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference?. Qual Life Res. 2013; 23(5):1427-34. DOI: 10.1007/s11136-013-0593-4. View

Rooney A, Brown P, Reijneveld J, Grant R . Depression in glioma: a primer for clinicians and researchers. J Neurol Neurosurg Psychiatry. 2013; 85(2):230-5. DOI: 10.1136/jnnp-2013-306497. View

Ganau M, Foroni R, Gerosa M, Zivelonghi E, Longhi M, Nicolato A . Radiosurgical options in neuro-oncology: a review on current tenets and future opportunities. Part I: therapeutic strategies. Tumori. 2014; 100(4):459-65. DOI: 10.1700/1636.17912. View

Yavas C, Zorlu F, Ozyigit G, Gurkaynak M, Yavas G, Yuce D . Prospective assessment of health-related quality of life in patients with low-grade glioma: a single-center experience. Support Care Cancer. 2011; 20(8):1859-68. DOI: 10.1007/s00520-011-1288-4. View

Simonova G, Novotny Jr J, Liscak R . Low-grade gliomas treated by fractionated gamma knife surgery. J Neurosurg. 2005; 102 Suppl:19-24. DOI: 10.3171/jns.2005.102.s_supplement.0019. View

Sizoo E, Dirven L, Reijneveld J, Postma T, Heimans J, Deliens L . Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. J Neurooncol. 2013; 116(2):283-90. DOI: 10.1007/s11060-013-1289-x. View

Ohgaki H . Epidemiology of brain tumors. Methods Mol Biol. 2008; 472:323-42. DOI: 10.1007/978-1-60327-492-0_14. View

10.

Maeda H . The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41:189-207. DOI: 10.1016/s0065-2571(00)00013-3. View

11.

Nomura K, Kazui H, Tokunaga H, Hirata M, Goto T, Goto Y . Possible roles of the dominant uncinate fasciculus in naming objects: a case report of intraoperative electrical stimulation on a patient with a brain tumour. Behav Neurol. 2012; 27(2):229-34. PMC: 5215405. DOI: 10.3233/BEN-110249. View

12.

Gondi V, Hermann B, Mehta M, Tome W . Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2012; 83(4):e487-93. PMC: 3462659. DOI: 10.1016/j.ijrobp.2011.10.021. View

13.

Jakola A, Gulati S, Weber C, Unsgard G, Solheim O . Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS One. 2011; 6(12):e28592. PMC: 3235141. DOI: 10.1371/journal.pone.0028592. View

14.

Ganau M . Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles. Clin Transl Oncol. 2013; 16(2):220-3. DOI: 10.1007/s12094-013-1114-1. View

15.

Sizoo E, Pasman H, Buttolo J, Heimans J, Klein M, Deliens L . Decision-making in the end-of-life phase of high-grade glioma patients. Eur J Cancer. 2011; 48(2):226-32. DOI: 10.1016/j.ejca.2011.11.010. View

16.

Yavas C, Zorlu F, Ozyigit G, Gurkaynak M, Yavas G, Yuce D . Health-related quality of life in high-grade glioma patients: a prospective single-center study. Support Care Cancer. 2011; 20(10):2315-25. DOI: 10.1007/s00520-011-1340-4. View

17.

Halkett G, Lobb E, Rogers M, Shaw T, Long A, Wheeler H . Predictors of distress and poorer quality of life in High Grade Glioma patients. Patient Educ Couns. 2015; 98(4):525-32. DOI: 10.1016/j.pec.2015.01.002. View

18.

Marson D, Martin R, Triebel K, Nabors L . Capacity to consent to research participation in adults with malignant glioma. J Clin Oncol. 2010; 28(24):3844-50. DOI: 10.1200/JCO.2009.27.9091. View

19.

Peters K, West M, Hornsby W, Waner E, Coan A, McSherry F . Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. J Neurooncol. 2014; 120(3):499-506. PMC: 4511848. DOI: 10.1007/s11060-014-1574-3. View

20.

Sboarina A, Foroni R, Minicozzi A, Antiga L, Lupidi F, Longhi M . Software for hepatic vessel classification: feasibility study for virtual surgery. Int J Comput Assist Radiol Surg. 2009; 5(1):39-48. DOI: 10.1007/s11548-009-0380-4. View